(Q34457426)

2 August 2017

1 reference

title

Evolving therapies: farnesyltransferase inhibitors (English)

1 reference

2 August 2017

W Thomas Purcell

1

1 reference

2 August 2017

Ross C Donehower

series ordinal

2

1 reference

2 August 2017

1 January 2002

1 reference

2 August 2017

Current Oncology Reports

1 reference

2 August 2017

4

1 reference

2 August 2017

29-36

1 reference

2 August 2017

1

1 reference

https://scigraph.springernature.com/pub.10.1007/s11912-002-0045-8

2 August 2017

0 references

cites work

Rational design of Ras prenyltransferase inhibitors as potential anticancer drugs

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11912-002-0045-8

Non-peptidic prenyltransferase inhibitors: diverse structural classes and surprising anti-cancer mechanisms

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11912-002-0045-8

Inhibitors of prenylation of Ras and other G-proteins and their application as therapeutics

21 January 2018

1 reference

12 December 2020

Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules

1 reference

12 December 2020

Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies

1 reference

12 December 2020

Protein prenylation: molecular mechanisms and functional consequences

1 reference

12 December 2020

RAS and leukemia: from basic mechanisms to gene-directed therapy

1 reference

12 December 2020

Clinical trials referral resource. Clinical trials with the farnesyl transferase inhibitor R115777

1 reference

12 December 2020

Targeting farnesyltransferase: is Ras relevant?

1 reference

12 December 2020

Ras-induced cellular events (review)

1 reference

12 December 2020

Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia

1 reference

12 December 2020

A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity.

1 reference

12 December 2020

Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo

1 reference

12 December 2020

A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer

1 reference

12 December 2020

Activity of SCH 66336, a tricyclic farnesyltransferase inhibitor, against human tumor colony-forming units

1 reference

12 December 2020

The farnesyl transferase inhibitor SCH 66336 induces a G(2) --> M or G(1) pause in sensitive human tumor cell lines

1 reference

12 December 2020

The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo

1 reference

12 December 2020

Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity

1 reference

12 December 2020

Inhibition of purified p21ras farnesyl:protein transferase by Cys-AAX tetrapeptides

1 reference

12 December 2020

Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice

1 reference

12 December 2020

The potential of farnesyltransferase inhibitors as cancer chemotherapeutics

1 reference

12 December 2020

Ras biochemistry and farnesyl transferase inhibitors: a literature survey

1 reference

12 December 2020

(+)-4-[2-[4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo[5, 6]cyclohepta[1,2-b]- pyridin-11(R)-yl)-1-piperidinyl]-2-oxo-ethyl]-1-piperidinecarboxamid e (SCH-66336): a very potent farnesyl protein transferase inhibitor as a novel antitumor agent

1 reference

12 December 2020

Blocking oncogenic Ras signaling for cancer therapy

1 reference

12 December 2020

Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines.

1 reference

12 December 2020

Protein prenylation: from discovery to prospects for cancer treatment.

1 reference

12 December 2020

Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic

1 reference

12 December 2020

Combination therapy with the farnesyl protein transferase inhibitor SCH66336 and SCH58500 (p53 adenovirus) in preclinical cancer models

1 reference

12 December 2020

Phase I and pharmacokinetic study of the orally administered farnesyl transferase inhibitor R115777 in patients with advanced solid tumors

1 reference

12 December 2020

Farnesyltransferase inhibitors: targeting the molecular basis of cancer

1 reference

12 December 2020

Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro.

1 reference

12 December 2020

Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial

1 reference

12 December 2020

Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors

1 reference

12 December 2020

Discovery of (R)-7-cyano-2,3,4, 5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3- (phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine (BMS-214662), a farnesyltransferase inhibitor with potent preclinical antitumor activity

1 reference

12 December 2020

K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors

1 reference

12 December 2020

Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer

1 reference

12 December 2020

Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development

1 reference

12 December 2020

Comparison of potential markers of farnesyltransferase inhibition

1 reference

12 December 2020

Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336.

1 reference

12 December 2020

Farnesyltransferase inhibitors: antineoplastic mechanism and clinical prospects

1 reference

12 December 2020

10.1007/S11912-002-0045-8

Identifiers

DOI

1 reference

Dimensions Publication ID

2 August 2017

1033639048

0 references

Fatcat ID

release_kru3sc32avcs3comzj4pleyzta

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/kru3sc32avcs3comzj4pleyzta

24 November 2022

mapped directly with Wikidata item

1 reference